Novo Nordisk has resubmitted its biologics license application (BLA) to the FDA for Awiqli (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with Type 2 diabetes.

About 38 million Americans have diabetes, and about 90% to 95% have Type 2 diabetes, according to the CDC. In Type 2 diabetes, cells don’t respond normally to insulin.

Awigli is a long-acting insulin analog that has been found to have a prolonged half-life of approximately seven days. Icodec binds to a protein in the blood, albumin, to form an inactive depot. It is released from albumin throughout the week. Awigli is injected subcutaneously.

If approved, Awiqli would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin inj

See Full Page